HRMY vs. SDGR, GPCR, PTGX, EWTX, KURA, SUPN, TARO, SYRE, ARDX, and RCUS
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Schrödinger (SDGR), Structure Therapeutics (GPCR), Protagonist Therapeutics (PTGX), Edgewise Therapeutics (EWTX), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Ardelyx (ARDX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.
Harmony Biosciences (NASDAQ:HRMY) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Harmony Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 79.1% of Schrödinger shares are held by institutional investors. 30.8% of Harmony Biosciences shares are held by insiders. Comparatively, 7.6% of Schrödinger shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Harmony Biosciences has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Schrödinger had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Schrödinger and 2 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.12 beat Schrödinger's score of 0.44 indicating that Harmony Biosciences is being referred to more favorably in the media.
Schrödinger received 7 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 60.29% of users gave Harmony Biosciences an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
Harmony Biosciences has a net margin of 22.30% compared to Schrödinger's net margin of -75.94%. Harmony Biosciences' return on equity of 28.26% beat Schrödinger's return on equity.
Harmony Biosciences currently has a consensus target price of $40.63, indicating a potential upside of 39.94%. Schrödinger has a consensus target price of $42.80, indicating a potential upside of 88.05%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Harmony Biosciences.
Summary
Harmony Biosciences beats Schrödinger on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harmony Biosciences Competitors List
Related Companies and Tools
